Semaglutide half-life: why once-weekly dosing works. - Reddit

How does semaglutide achieve a 1-week half-life?

Native GLP-1 peptide, the hormone semaglutide mimics, has a circulating half-life of just 1–2 minutes. It is rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4) and cleared by the kidneys. Creating a GLP-1 receptor agonist with therapeutic once-weekly duration required deliberate chemical engineering at two levels.

DPP-4 resistance

DPP-4 cleaves peptides at the second amino acid position from the N-terminus. In native GLP-1, that position is an alanine residue, which is the DPP-4 recognition site. Semaglutide substitutes the amino acid at position 8 with alpha-aminoisobutyric acid (Aib), a modification that eliminates DPP-4 cleavage while preserving GLP-1 receptor binding. This is the same approach used in earlier GLP-1 agonists but is necessary as a foundation.

Albumin binding via fatty acid chain

The key innovation that makes semaglutide once-weekly (rather than once-daily like liraglutide) is its fatty acid modification. Semaglutide carries a C18 fatty diacid chain attached via a synthetic linker. This chain allows semaglutide to bind reversibly to albumin — the most abundant protein in blood plasma.

Albumin binding does two things simultaneously. First, it slows renal clearance: albumin is too large to be filtered by the kidney, so semaglutide attached to albumin is protected from urinary excretion. Second, it shields semaglutide from proteolytic enzymes while it is albumin-bound, slowing degradation.

The net result: a plasma half-life of approximately 165 hours — long enough that once-weekly dosing maintains plasma concentrations within the therapeutic window across the full 7-day interval.

What does semaglutide’s half-life mean for dosing timing and missed doses?

Once-weekly dosing produces plasma levels that fluctuate within a narrow band across the week, rather than peaking sharply after each injection and dropping toward zero before the next. The trough-to-peak ratio at steady state is approximately 1:1.4, meaning the lowest concentration (just before the next dose) is about 70% of the peak concentration shortly after injection.

This matters practically because it means:

• No daily injection required. The 7-day dosing interval is pharmacokinetically supported, not arbitrary.
• Day of the week does not matter. Because the half-life is approximately equal to the dosing interval, steady-state levels are similar regardless of whether you inject Monday or Friday, as long as the interval is consistent.
• Steady state takes 4-5 weeks. Plasma levels accumulate with each weekly dose, reaching steady state after approximately 4-5 half-lives. This is why dose-escalation protocols do not increase the dose until week 5 at the earliest — the full pharmacological effect of each dose level is not apparent until steady state is established.

What does the half-life tell you about a missed dose?

Because the half-life is approximately 1 week, missing a single dose does not produce an immediate collapse in plasma concentrations. After 1 half-life (1 week) of no dosing, levels fall to approximately 50% of the prior steady-state concentration. After 2 weeks, approximately 25%. After 4–5 weeks, levels become effectively negligible.

Standard clinical guidance for a missed weekly dose:

• If the missed dose was less than 5 days ago and the next scheduled dose is more than 48 hours away, take the missed dose and then resume the regular schedule.
• If the next scheduled dose is within 48 hours, skip the missed dose and take the next scheduled dose on time. Do not take two doses to compensate.

If you have been off semaglutide for several weeks and are restarting, a clinician may recommend restarting at a lower dose and re-escalating — GI tolerance that was achieved during the original escalation may need to be rebuilt.

What happens when you stop semaglutide?

After stopping semaglutide, plasma levels decline across approximately 4-5 half-lives — about 5 weeks before levels become negligible. During this washout period:

• GI effects persist initially. Reduced gastric emptying and appetite suppression continue while plasma levels remain meaningful, then diminish as levels fall.
• Appetite typically returns. Most patients experience increased appetite and eventual weight regain after stopping, consistent with the STEP-4 withdrawal data. The degree and timeline vary between individuals.
• Surgical anesthesia consideration. Semaglutide’s effect on gastric emptying creates aspiration risk under general anesthesia. Current clinical guidance recommends stopping semaglutide at least 1 week (one dosing interval) before elective procedures requiring general anesthesia, though some anesthesiologists request longer washout periods. This decision should be made with your prescribing clinician and surgical team.

Compounded semaglutide and pharmacokinetics

Compounded semaglutide prepared by licensed USA 503A pharmacies uses semaglutide as the active ingredient. The pharmacokinetic properties described above — including the half-life — are properties of semaglutide the molecule, not of any specific branded or compounded formulation.

Compounded semaglutide is not FDA-approved and is not the same as branded products. It is a compounded medication. Its use is a clinical decision made by a licensed prescribing clinician, and the dose prescribed is based on an individual evaluation.

For more on how semaglutide works as a GLP-1 receptor agonist, including its effects on appetite signaling and weight management, see the semaglutide overview.

Frequently asked questions